Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label, Prospective, Randomized, Active-controlled Study on the Efficacy and Safety of Oral Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis After Major Gynecological Cancer Surgery.

NCT04999176 is registered in ClinicalTrials.gov with André Luiz Malavasi Longo de Oliveira as lead sponsor.

NCT NCT04999176
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04999176 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label, Prospective, Randomized, Active-controlled Study on the Efficacy and Safety of Oral Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis After Major Gynecological Cancer Surgery.
Lead sponsor
André Luiz Malavasi Longo de Oliveira
Phase
Phase 3
Overall status
Unknown status
Start date
October 22, 2020
Completion date
July 15, 2024
Enrollment
440 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, rivaroxaban, thromboprophylaxis, venous thromboembolism